Anordrin compositions and methods for treating diseases

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11911397
APP PUB NO 20210069212A1
SERIAL NO

16953168

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides methods and compositions for treating cancer, reducing side effects, and reducing postmenopausal symptoms comprising anordrin or analog thereof (such as anordrin) alone or in combination with at least one other agent selected from the group consisting of tamoxifen, raloxifene or functional equivalent thereof, and an aromatase inhibitor.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ZHEJIANG JIACHI DEVELOPMENT PHARMACEUTICALS LTD; CHANGZHOU RUIMING PHARMACEUTICAL COMPANY, LTD.

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Shi, Huijuan Hangzhou, CN 4 11
Xu, Wenping Hangzhou, CN 10 18
Yang, Jun Hangzhou, CN 722 7494

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Aug 27, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 27, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 27, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00